RECO in the Endovascular Treatment of Acute Ischemic Stroke

NCT04840719 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-04-14

No results posted yet for this study

Summary

Investigate Reco ® ,the first clot retriever in china as the primary therapyand remedies in the real world.

Conditions

  • Intracranial Artery Occlusion With Infarction (Disorder)

Interventions

DEVICE

RECO

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Zhongrong Miao, PhD,MD · Capital Medical University, Beijing Tiantan Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-22
Primary Completion
2021-12-31
Completion
2022-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04840719 on ClinicalTrials.gov